0240-OL:HK:HK-BUILD KING HOLD (HKD)

COMMON STOCK | Other |

Last Closing

USD 0.89

Change

-0.01 (-1.11)%

Market Cap

N/A

Volume

0.03M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

There is no Profile data available for 0240-OL.HK. Address:

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-20 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap
1863:HK China Longevity Group Company ..

N/A

USD 1.17B
8355:HK I-CONTROL

-0.01 (-2.86%)

USD 0.39B
8343:HK HongGuang Lighting Holdings Co..

-0.02 (-5.19%)

USD 0.31B
0648:HK CHINA RENJ

N/A

USD 0.12B
0177-OL:HK JIANGSU EXPRESS

+0.10 (+1.32%)

N/A
0243-OL:HK QPL INT'L

+0.04 (+32.76%)

N/A
0259-OL:HK YEEBO (INT'L H)

+0.02 (+0.95%)

N/A
0182-OL:HK CHINA WINDPOWER

-0.01 (-1.89%)

N/A
0272-OL:HK SHUI ON LAND

+0.01 (+1.79%)

N/A
0187-OL:HK JINGCHENG MAC

N/A

N/A

ETFs Containing 0240-OL:HK

N/A

Market Performance

  Market Performance vs. Industry/Classification (Other) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.61% 29% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.61% 28% F 35% F
Trailing 12 Months  
Capital Gain -20.54% 41% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.54% 38% F 44% F
Trailing 5 Years  
Capital Gain 4.71% 72% C 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.71% 72% C 72% C
Average Annual (5 Year Horizon)  
Capital Gain 9.80% 72% C 74% C
Dividend Return 9.80% 69% C- 72% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.71% 53% F 55% F
Risk Adjusted Return 36.69% 81% B- 82% B
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (HKD)

Quarterly Financials (HKD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike